The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

A plateau in treatment effect can be seen for the current ‘one-size-fits-all’ approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment (TME) is largely immunosuppressed, however a subgroup of patient...

Descrizione completa

Dettagli Bibliografici

Autori principali:	James M. Lonie, Sandra Brosda, Vanessa F. Bonazzi, Lauren G. Aoude, Kalpana Patel, Ian Brown, Sowmya Sharma, Guy Lampe, Venkateswar Addala, Lambros T. Koufariotis, Scott Wood, Nicola Waddell, Riccardo Dolcetti, Andrew P. Barbour
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-10-01
Serie:	Frontiers in Immunology
Soggetti:	oesophageal adenocarcinoma tumour microenvironment neoadjuvant therapy survival treatment response
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1220129/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!